Feasibility of a Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis

Tuberculosis Clinical Trial

Official title:

Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01525134
• Other study ID #: DMID10-0001
• Secondary ID: NA_00038297
• Status: Active, not recruiting
• Phase: N/A
• First received: January 20, 2012
• Last updated: February 1, 2012
• Start date: January 2011
• Est. completion date: April 2012

Study information

• Verified date: January 2012
• Source: Tuberculosis Clinical Diagnostics Research Consortium
• Contact: n/a
• Is FDA regulated: No
• Health authority: Uganda: National Council for Science and TechnologyUganda: Research Ethics CommitteeUnited States: Federal GovernmentUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine lipoarabinomannan (LAM) test in detecting tuberculosis in HIV-infected adults.

A secondary study objective is to determine the accuracy, efficiency, costs, and cost-effectiveness of various combinations of Tuberculosis (TB) diagnostic tests, including the novel Xpert MTB/Rif test.

Description:

Background: Tuberculosis (TB) incidence and mortality have increased dramatically as a result of the HIV epidemic. In parts of sub-Saharan Africa, TB is the leading cause of death among HIV-infected patients and approximately 50% of TB patients are HIV co-infected. Early treatment of TB is hindered by the lack of rapid, accurate diagnostic modalities that can be applied in resource-constrained settings. Mycobacterial culture is the laboratory standard for diagnosis of active TB, but it is costly, requires access to specialized laboratories, and takes weeks to provide results. Sputum smear microscopy detects less than half of HIV-infected TB cases in many settings. The Global Plan to Stop TB has prioritized the development of simple, accurate, inexpensive tests for TB case detection in HIV-positive individuals.

LAM: As a strategy for rapid TB diagnosis, the detection of Mycobacterium tuberculosis antigens has been explored over several decades. Lipoarabinomannan (LAM), a glycolipid component of the outer cell wall of mycobacteria, is an attractive diagnostic target for several reasons: it is heat-stable; cleared by the kidney; detectable in urine; and as a bacterial product, has the theoretical potential to discriminate active TB from latent TB infection independent of human immune responses. A urine test could facilitate TB diagnosis in patients in whom sputum is uninformative or not obtainable, and lacks the infection-control risks associated with sputum production or blood collection. Urine LAM detection may be amenable to simple, rapid, inexpensive point-of-care platforms.

This is a prospective study to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine LAM test in detecting tuberculosis in HIV-infected adults. HIV-positive adults suspected to have TB will be enrolled after providing informed consent. Urine will be obtained for testing using the novel lateral flow urine LAM assay and an existing ELISA-based urine LAM assay. Conventional microbiological tests for TB and chest x-rays will also be performed. These tests will be performed on all participants enrolled (target sample size = 500).

A secondary study objective is to determine the accuracy, efficiency, costs, and cost-effectiveness of various combinations of TB diagnostic tests, including the novel Xpert MTB/Rif test. The Xpert MTB/Rif test will be performed on a subset of participants (approximately 200 participants out of the total of 500 participants we expect to enroll for the LAM component of the study.)

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 504
• Est. completion date: April 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria (Individuals must meet all of the following inclusion criteria in order to be eligible to participate):

• Informed consent

• Suspected active tuberculosis

• Willingness and ability to comply with study procedures

• Any one or more of the following:

• Current cough

• Fever at any time within the preceding 4 weeks

• Night sweats at any time within the preceding 4 weeks

• Weight loss within the preceding 4 weeks

• HIV-positive based on any one or more of the following:

• written results of a positive HIV antibody test, and/or

• written results of a positive HIV viral load, and/or

• documentation in the medical record of positive HIV status by a treating clinician.

Exclusion Criteria (Any subjects meeting any of the following exclusion criteria at baseline will be excluded from study participation):

• Multidrug tuberculosis treatment for greater than two days within the previous 60 days

• Unwillingness or inability to provide a urine sample

• Known chronic pulmonary condition, e.g. asthma, chronic obstructive pulmonary disease, emphysema

• Respiratory distress, defined as respiratory rate of >30 or oxygen saturation <90%

• Any specific condition that in the judgment of the investigator precludes participation because it could affect a subject's safety.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Tuberculosis
• Tuberculosis, Miliary
• Tuberculosis, Pulmonary

Intervention

Device:
• Alere "Determine" lateral-flow urine lipoarabinomannan assay
lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro. Manufacturer: Alere
• Alere "Clearview" ELISA urine LAM assay
ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro. Manufacturer: Alere.

Locations

Country	Name	City	State
Uganda	Infectious Diseases Institute, Makerere University	Kampala
Uganda	Mulago National Referral Hospital	Kampala

Sponsors (2)

Lead Sponsor	Collaborator
Tuberculosis Clinical Diagnostics Research Consortium	Makerere University

Country where clinical trial is conducted

Uganda, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity of the lateral-flow urine LAM assay (LF-LAM)	Conventional TB tests (mycobacterial blood & sputum culture) will be the reference standard used to calculate sensitivity of the LF-LAM test; Sensitivity is defined as TP/(TP+FN), or the number of true positives over (the number of true positives + the number of false negatives); "true positive" = a positive LF-LAM result in a patient also having =1 culture positive for M. tuberculosis; "false negative" = a negative LF-LAM result in a patient also having =1 culture positive for M. tuberculosis	One year	No
Primary	Failure rate of the lateral-flow urine LAM assay	Failure rate expressed as the proportion of lateral flow urine LAM tests that require repeating due to an unevaluable initial result	One year	No
Primary	Inter-reader variability of the lateral-flow urine LAM assay	Expressed as the percent agreement	One year	No
Primary	Specificity of the lateral-flow urine LAM assay (LF-LAM)	Conventional TB tests (blood & sputum culture) will be the reference standard used to calculate specificity (Sp) of the LF-LAM; Sp=TN/(TN+FP), or #true negatives / (#true negatives + #false positives); "true negative" = negative LF-LAM in "Not TB" patient; "false positive" = positive LF-LAM in "Not TB" patient; "Not TB" = meets all criteria below; no sputum/blood culture positive for MTB; no smear microscopy positive for acid-fast bacilli; no granulomas/caseous necrosis on histopathology; no clinical response to TB treatment; a plausible alternative diagnosis	One year	No
Secondary	Sensitivity of the ELISA-based urine LAM test	Conventional TB tests (mycobacterial blood & sputum culture) will be the reference standard used to calculate sensitivity of the ELISA LAM test; Sensitivity is defined as TP/(TP+FN), or the number of true positives over (the number of true positives + the number of false negatives); "true positive" = a positive ELISA LAM result in a patient also having =1 culture positive for M. tuberculosis; "false negative" = a negative ELISA LAM result in a patient also having =1 culture positive for M. tuberculosis	One year	No
Secondary	Diagnostic yield (expressed as number of TB cases detected) of various diagnostic strategies (see description)	Diagnostic yield will be measured for strategies including a) lateral flow urine LAM testing plus sputum smear microscopy; b) ELISA urine LAM testing plus sputum smear microscopy; c) sputum smear microscopy plus sputum culture; d) sputum culture plus mycobacterial blood culture.	One year	No
Secondary	Time to diagnosis (expressed in days) of various diagnostic strategies (see description)	Time to diagnosis will be measured for strategies including a) lateral flow urine LAM testing plus sputum smear microscopy; b) ELISA urine LAM testing plus sputum smear microscopy; c) sputum smear microscopy plus sputum culture; d) sputum culture plus mycobacterial blood culture.	One year	No
Secondary	Accuracy, efficiency, costs, and cost-effectiveness of various combinations of TB diagnostic tests	TB diagnostic tests to be included in this analysis: sputum smear microscopy, sputum culture, mycobacterial blood culture, chest X-ray, lateral-flow urine LAM testing, ELISA urine LAM testing, and Xpert MTB/Rif.	One year	No
Secondary	Satisfaction of lateral-flow urine LAM test operators	Based on questionnaire assessment	One year	No
Secondary	Specificity (Sp) of the ELISA-based urine LAM test	Conventional TB tests (blood & sputum culture) will be the reference standard used to calculate Sp of ELISA LAM; Sp=TN/(TN+FP), or #true negatives / (#true negatives + #false positives); "true negative" = negative ELISA LAM in "Not TB" patient; "false positive" = positive ELISA LAM in "Not TB" patient; "Not TB" = meets all criteria below; no sputum/blood culture positive for MTB; no smear microscopy positive for acid-fast bacilli; no granulomas/caseous necrosis on histopathology; no clinical response to TB treatment; a plausible alternative diagnosis	One year	No

External Links

•   Tuberculosis Clinical Diagnostics Research Consortium